A.G.P./Alliance Global Partners
590 Madison Ave., 28th Floor
New York, NY 10022
January 25, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: | CNS Pharmaceuticals Inc. (the “Company”) | |
Registration Statement on Form S-1 (File No. 333-275973) (the “Registration Statement”) |
Ladies and Gentlemen:
Reference is made to our letter, filed as correspondence via EDGAR on January 24, 2024, in which A.G.P / Alliance Global Partners as lead Placement Agent, joined the Company’s request for acceleration of the effective date of the above-referenced Registration Statement for 5:00 pm Eastern Time on January 25, 2024, or as soon thereafter as practicable, in accordance with Rule 461 under the Securities Act of 1933, as amended. The Company is no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.
Very truly yours,
| |||
A.G.P / Alliance Global Partners | |||
By: | /s/ Thomas J. Higgins | ||
Name: | Thomas J. Higgins | ||
Title: | Managing Director | ||